In a major ruling that strengthens the hands of insurance companies against fraudulent claims, the Delhi State Consumer Disputes Redressal Commission has overturned a lower forum’s order and upheld the decision of an insurance firm to reject a medical claim due to fabricated hospital and laboratory records.
The State Commission set aside a district forum’s directive that had previously ordered Bajaj Allianz General Insurance Company Ltd. to payout a policyholder claim. The apex state consumer body ruled that when an insurance claim is built on manipulated documents, the insurer is entirely within its legal rights to reject it.
The matter began when the complainant, Pooja Kumari, bought an online health insurance policy from Bajaj Allianz valid from July 2021 to July 2022, with a sum insured of ₹3 lakh. In April 2022, she was admitted to Mahavir Multispeciality Hospital in New Delhi for five days to get treated for macrocytic anaemia. She paid the hospital bill of ₹41,530 out of her own pocket and subsequently filed for reimbursement.
When Bajaj Allianz rejected her claim following an internal investigation, she approached the District Consumer Disputes Redressal Commission-VI. The district forum ruled in her favor, declaring the rejection a “deficiency in service” and ordering the insurer to pay the bill amount along with ₹25,000 in compensation and interest. Challenging the verdict, the insurance company moved the State Commission in an appeal.
The turning point in the insurance company’s appeal was a detailed investigation report submitted by an external agency, Aizon Healthcare Services. Hired by Bajaj Allianz to audit the claim files, the agency uncovered an extensive paper trail of irregularities that suggested the entire hospitalization story had been systematically manipulated. What looked like a standard medical claim on the surface quickly fell apart once investigators cross referenced the hospital’s internal timestamps, patient statements, and legal licensing status.
The most massive timeline error found by investigators involved a medical injection that was allegedly administered after the patient had already left the building. According to the hospital’s official discharge summary, the policyholder was formally discharged and cleared to leave the facility at 12:42 PM on April 5, 2022. However, the hospital’s internal inpatient nursing charts logged that a nurse checked the patient’s vital signs and administered an injection at 1:00 PM on that very same day. This twenty-minute contradiction heavily indicated to the investigators that the bedside charts were being backdated or completely fabricated after the fact.
Furthermore, the agency uncovered massive contradictions between what the patient claimed she suffered from and what the hospital staff wrote down. During her formal investigative interview, the policyholder explicitly stated that she was rushed to the hospital because she was suffering from a high-grade fever, continuous vomiting, and acute abdominal pain.
Yet, when investigators pulled the actual inpatient case sheets, the attending staff had recorded her symptoms as a mild, low-grade fever, general tiredness, and standard body aches. This complete disconnect in clinical symptoms raised red flags about whether the patient was ever actually treated for the conditions she described.
Finally, when investigators checked the hospital’s licenses and discovered it was operating its inpatient ward illegally. Aizon Healthcare Services discovered that Mahavir Multispeciality Hospital did not possess a valid registration under the Directorate General of Health Services (DGHS) to admit and treat overnight patients at the time of the treatment.
While the hospital had applied for the mandatory DGHS registration back in May 2021, the government had kept the application strictly on hold. Because the facility lacked the basic legal authority to run an inpatient department in April 2022, the commission noted that the entire five-day stay was fundamentally compromised from a legal standpoint.
The final turning point to the policyholder’s case came from the very laboratory reports submitted to prove the treatment. The reports carried the name of Dr. K.D. Gandhi, an MD Pathologist, as the verifying doctor. However, when investigators contacted him directly, Dr. Gandhi gave a clear, written statement saying, “This report was not verified by me.” The bench, comprising State Commission President Justice Sangita Dhingra Sehgal and Member Bimla Kumari, observed that the district forum had committed a major oversight by ignoring these facts.
In their judgment, the judges pointed out that the lower court had made a “glaring error” by assuming the treatment was completely legitimate when the primary doctor named on the reports had directly denied validating them. Upholding the insurance company’s decision to invoke the standard “Fraud Clause” of the policy, the bench explicitly stated:
“If any fraudulent means or devices are used, or if forged and/or fabricated documents are received by the insurer to obtain a claim, all benefits under the policy shall be rendered void, and any payments thereunder shall be forfeited.”
The judges concluded that because the documents were clearly manipulated, no “deficiency of service” could be pinned on Bajaj Allianz. The bench remarked:
“We are of the view that the appellant was justified in repudiating the claim of the respondent in accordance with the terms and conditions of the policy… Consequently, the order dated 17.10.2023 passed by the District Commission is set aside.”
This judgment marks a significant shift in how consumer courts are balancing policyholder protection with corporate fraud detection. Historically, consumer courts in Delhi and across India have taken a strict stance against insurance companies, often penalizing them for delaying payouts over minor procedural errors or vague suspicions. For instance, in separate recent matters, the same State Commission heavily penalized public insurers like United India Insurance for stalling genuine medical claims without concrete evidence.
However, legal experts note that this latest ruling draws a hard line. It sends a clear message to the public and healthcare providers, while the courts will continue to protect consumers from unfair insurance delays, they will not tolerate fabricated medical evidence or compromised laboratory reports. By fully validating the “Fraud Clause,” this judgment establishes that insurance firms have a robust legal backing to reject claims out of hand if a clear paper trail of forgery is proven.
